Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Polynovo ( (AU:PNV) ) has issued an announcement.
Polynovo Limited announced the appointment of Robert Douglas as a director, effective October 14, 2025. This appointment is part of the company’s strategic efforts to strengthen its leadership team and enhance its market position in the medical technology sector. The announcement does not indicate any current securities or contract interests held by the new director, suggesting a fresh start in his role.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
Polynovo Limited operates in the medical technology industry, focusing on the development and commercialization of innovative medical devices. The company is known for its NovoSorb technology, which is used in various medical applications, including wound care and tissue regeneration.
YTD Price Performance: -37.99%
Average Trading Volume: 3,460,637
Technical Sentiment Signal: Sell
Current Market Cap: A$873.9M
See more insights into PNV stock on TipRanks’ Stock Analysis page.